4.77
price down icon1.45%   -0.07
after-market アフターアワーズ: 4.77
loading
前日終値:
$4.84
開ける:
$4.87
24時間の取引高:
182.62K
Relative Volume:
0.92
時価総額:
$216.06M
収益:
$84.82M
当期純損益:
$-21.43M
株価収益率:
-9.7347
EPS:
-0.49
ネットキャッシュフロー:
$-27.23M
1週間 パフォーマンス:
+10.67%
1か月 パフォーマンス:
-2.85%
6か月 パフォーマンス:
-23.68%
1年 パフォーマンス:
-61.31%
1日の値動き範囲:
Value
$4.68
$4.90
1週間の範囲:
Value
$4.29
$5.005
52週間の値動き範囲:
Value
$3.55
$16.11

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
名前
Y Mabs Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
646-885-8505
Name
住所
202 CARNEGIE CENTER, PRINCETON, NY
Name
職員
107
Name
Twitter
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
YMAB's Discussions on Twitter

YMAB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
4.77 217.87M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-22 ダウングレード BofA Securities Neutral → Underperform
2024-11-18 開始されました Oppenheimer Outperform
2024-08-16 開始されました Cantor Fitzgerald Overweight
2024-06-28 開始されました Truist Buy
2023-05-10 アップグレード Wedbush Neutral → Outperform
2023-04-03 ダウングレード Guggenheim Buy → Neutral
2023-01-27 ダウングレード Morgan Stanley Equal-Weight → Underweight
2023-01-05 ダウングレード Cowen Outperform → Market Perform
2022-12-02 ダウングレード BofA Securities Buy → Neutral
2022-10-31 ダウングレード JP Morgan Neutral → Underweight
2022-10-31 ダウングレード Wedbush Outperform → Neutral
2022-07-06 再開されました Canaccord Genuity Buy
2022-06-24 開始されました BMO Capital Markets Outperform
2022-02-03 再開されました Guggenheim Buy
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-11-16 ダウングレード JP Morgan Overweight → Neutral
2021-05-07 アップグレード BofA Securities Neutral → Buy
2021-04-23 再開されました Cowen Outperform
2021-03-22 再開されました JP Morgan Overweight
2021-01-15 ダウングレード BofA Securities Buy → Neutral
2020-11-09 繰り返されました H.C. Wainwright Buy
2020-05-05 開始されました Barclays Overweight
2020-05-01 開始されました Janney Buy
2020-04-29 開始されました Morgan Stanley Equal-Weight
2019-12-24 開始されました JP Morgan Overweight
2019-11-20 開始されました Guggenheim Buy
2019-09-04 開始されました Wedbush Outperform
2019-04-01 開始されました H.C. Wainwright Buy
2018-10-16 開始されました BTIG Research Buy
2018-10-16 開始されました BofA/Merrill Buy
すべてを表示

Y Mabs Therapeutics Inc (YMAB) 最新ニュース

pulisher
03:54 AM

Will Y mAbs Therapeutics Inc. stock benefit from AI tech trendsHigh-profit capital plays - jammulinksnews.com

03:54 AM
pulisher
12:26 PM

Should I buy Y mAbs Therapeutics Inc. stock before earningsFree Predictions - jammulinksnews.com

12:26 PM
pulisher
Jul 24, 2025

Will Y mAbs Therapeutics Inc. stock split in the near futureUnprecedented profit potential - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Y mAbs Therapeutics Inc. stockExplosive capital gains - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Following a 61% decline over last year, recent gains may please Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) institutional owners - simplywall.st

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Y mAbs Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Y mAbs Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Y mAbs Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional

Jul 21, 2025
pulisher
Jul 15, 2025

Y-Mabs Therapeutics Elects New Director at Annual Meeting - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Y-mAbs Therapeutics announces results of annual shareholder meeting votes - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Y mAbs Therapeutics Inc. stock price move sharplySafe and Smart Investment Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

2nd Circ. Affirms Biotech Founder's Win In Trading Suit - Law360

Jul 14, 2025
pulisher
Jul 11, 2025

Transcript : Y-mAbs Therapeutics, Inc.Shareholder/Analyst Call - MarketScreener

Jul 11, 2025
pulisher
Jul 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Jul 04, 2025
pulisher
Jul 02, 2025

YMAB SEC FilingsY-Mabs Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 02, 2025
pulisher
Jun 25, 2025

Is Y-mAbs Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 15, 2025

Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com India

Jun 14, 2025
pulisher
Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 09, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 09, 2025

Y Mabs Therapeutics Inc (YMAB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Y Mabs Therapeutics Inc (YMAB) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Rossi Michael J
PRESIDENT & CEO
Mar 07 '25
Sale
5.20
3,917
20,368
137,083
Gad Thomas
CHIEF BUSINESS OFFICER
Mar 07 '25
Sale
5.23
10,810
56,536
202,721
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):